Stayble Therapeutics ABOSTO:STABL 28 EBIT per Share is kr-0.17 as of Mar. 2026. GuruFocus rates OSTO:STABL with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,172 Biotechnology companies, Stayble Therapeutics AB ranks better than 90.36% on this metric.
Stayble Therapeutics AB's EBIT per Share for the
three
months ended in Mar. 2026 was kr-0.09.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.17.
During the past 3 years, the average EBIT per Share Growth Rate was 59.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 38.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Stayble Therapeutics AB's EBIT per Share or its related term are showing as below:
OSTO:STABL'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -79.6 Med: -7.5 Max: 59.4
Current: 59.4
During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Stayble Therapeutics AB was 59.40% per year. The lowest was -79.60% per year. And the median was -7.50% per year.
OSTO:STABL's 3-Year EBIT Growth Rate is ranked better than 90.36% of 1172
companies
in the Biotechnology industry
Industry Median: 15.4
vs OSTO:STABL: 59.40
Stayble Therapeutics AB (OSTO:STABL) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Stayble Therapeutics AB EBIT per Share Related Terms
Stayble Therapeutics AB EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.17
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stayble Therapeutics AB (OSTO:STABL) has a EBIT per Share of kr-0.17 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Stayble Therapeutics AB and its competitors. According to the industry distribution chart, Stayble Therapeutics AB ranks #113 out of 1172 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Stayble Therapeutics AB's EBIT per Share too high?
Stayble Therapeutics AB's current EBIT per Share is kr-0.17. Based on the distribution chart, Stayble Therapeutics AB ranks #113 out of 1172 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Stayble Therapeutics AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Stayble Therapeutics AB's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stayble Therapeutics AB ranks #113 out of 1172 companies for EBIT per Share. This places Stayble Therapeutics AB in the top 10% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Stayble Therapeutics AB and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stayble Therapeutics AB's current EBIT per Share is kr-0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stayble Therapeutics AB stock overvalued right now?
Stayble Therapeutics AB (OSTO:STABL) has a current EBIT per Share of kr-0.17. The current EBIT per Share is kr-0.17. Stayble Therapeutics AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Stayble Therapeutics AB (OSTO:STABL), the current EBIT per Share is kr-0.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.
28GF Score
Get the complete analysis for OSTO:STABL
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:STABL has been successfully added to your 
